{"brief_title": "Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)", "brief_summary": "To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL). To determine the long-term safety of acyclovir in the AIDS-related complex (ARC) patient with HL. To monitor the progression of HIV disease in the HL patient and compare to existing historical control data.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Acyclovir", "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Topical antifungal therapy. Patient must have: - Newly diagnosed clinical and histological hairy leukoplakia. - Positive HIV antibody by licensed ELISA or Western blot. Exclusion Criteria Co-existing Condition: Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Concurrent Medication: Excluded within 2 weeks of study entry: - Systemic antifungal treatment. - Excluded within 6 weeks of study entry: - Immunomodulators. - Systemic antiviral treatment. Patients with AIDS or a history of intolerance or allergy to acyclovir are excluded. Prior Medication: Excluded within 2 weeks of study entry: - Systemic antifungal. - Excluded within 6 weeks of study entry: - Immunomodulators. - Systemic antiviral treatment. - Excluded within 8 weeks of study entry: - Zidovudine (AZT) or other antiretroviral therapy.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002026.xml"}